The Genome as a Tool for Drug Discovery and Development the Case for Embracing Complexity

21 October 2006 , By Dr Kenneth C. Carter , Fall 2006
Posted in Archive, Enabling Technologies | Tagged Academic, AI / data analytics / healthtech / informatics, Analysis, Animal models, Assay development optimisation & technology, Biochemistry, Biomarkers, Business, Cell / tissue culture, Cell culture, Cell therapy, Cellular & Molecular biology, Cellular assays, Clinical trials, Drug development, Drug discovery, Drug targets, Gene therapy, Genetics / genomes, Genetics / genomics, Genomics, High Throughput screening, Lead discovery, Lead optimisation, Metabolomics, Molecular medicine, Patent Law, Pharmacogenomics, Pharmokinetics, Protein chemistry / Proteomics, Regulatory, RNA, Screening, Stem cells, System biology, Systems biology, Target validation, Theranostics, Toxicology The Genome as a Tool for Drug Discovery and Development the Case for Embracing Complexity By Dr Kenneth C. Carter Conventional drug discovery and development is centred on a paradigm in which 'validated' targets are subjected to in vitro screens for the identification of new drug candidates. Molecular profiling using genomic approaches is becoming an [...]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!